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Abstract
Background: The elastolytic enzyme matrix metalloproteinase (MMP)-12 has been implicated in the
development of airway inflammation and remodeling. We investigated whether human airway smooth muscle cells
could express and secrete MMP-12, thereby participating in the pathogenesis of airway inflammatory diseases.
Methods: Laser capture microdissection was used to collect smooth muscle cells from human bronchial biopsy
sections. MMP-12 mRNA expression was analysed by quantitative real-time RT-PCR. MMP-12 protein expression
and secretion from cultured primary airway smooth muscle cells was further analysed by Western blot. MMP-12
protein localization in bronchial tissue sections was detected by immunohistochemistry. MMP-12 activity was
determined by zymography. The TransAM AP-1 family kit was used to measure c-Jun activation and nuclear
binding. Analysis of variance was used to determine statistical significance.
Results: We provide evidence that MMP-12 mRNA and protein are expressed by in-situ human airway smooth
muscle cells obtained from bronchial biopsies of normal volunteers, and of patients with asthma, COPD and
chronic cough. The pro-inflammatory cytokine, interleukin (IL)-1β, induced a >100-fold increase in MMP-12 gene
expression and a >10-fold enhancement in MMP-12 activity of primary airway smooth muscle cell cultures.
Selective inhibitors of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphatidylinositol 3-
kinase reduced the activity of IL-1β on MMP-12, indicating a role for these kinases in IL-1β-induced induction and
release of MMP-12. IL-1β-induced MMP-12 activity and gene expression was down-regulated by the
corticosteroid dexamethasone but up-regulated by the inflammatory cytokine tumour necrosis factor (TNF)-α
through enhancing activator protein-1 activation by IL-1β. Transforming growth factor-β had no significant effect
on MMP-12 induction.
Conclusion: Our findings indicate that human airway smooth muscle cells express and secrete MMP-12 that is
up-regulated by IL-1β and TNF-α. Bronchial smooth muscle cells may be an important source of elastolytic
activity, thereby participating in remodeling in airway diseases such as COPD and chronic asthma.
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Matrix metalloproteinases (MMPs) are a group of zinc-
dependent structurally-related extracellular matrix (ECM)
degrading proteinases that regulate ECM composition
and are also able to cleave non-matrix proteins including
growth factors, chemoattractants and cell surface recep-
tors [1,2] There are more than 20 MMPs that can degrade
every component of ECM and each MMP has its own sub-
strate specificity [3-5]. Because of their ability to degrade
ECM proteins, MMPs mediate tissue remodeling under
physiological and pathological circumstances. The prote-
olytic activity of MMPs is counterbalanced by the presence
of tissue inhibitors of metalloproteinases (TIMPs), which
naturally inhibit MMPs by direct binding [6]. MMP-12,
also called macrophage metalloelastase, was originally
detected in alveolar macrophages of cigarette smokers [7].
It is secreted as a 54 kDa inactive pro-enzyme which is
activated by proteolytic cleavage of the prodomain fol-
lowed by processing into two active enzymes of 45 kDa
and 22 kDa [7]. MMP-12 degrades a broad range of ECM
proteins, including elastin, type IV collagen, fibronectin,
laminin and gelatin [8,9], and is involved in turnover of
the matrix, cell migration, tissue repairing and remode-
ling. In addition, MMP-12 can activate other MMPs, for
example, MMP-2 and -3, leading to subsequent degrada-
tion of other ECM proteins [10].
MMP-12 may facilitate airway inflammation by stimulat-
ing migration of inflammatory cells such as monocytes
and macrophages to inflammatory sites, and mediate air-
way remodeling by degrading ECM proteins through its
enzymatic activity or through mediating inflammatory
cytokines to induce other MMPs, including MMP-2, -9, -
13 and -14, in lung [11]. Overproduction of MMP-12
causes pathological ECM protein breakdown and exces-
sive airway remodeling, which has been implicated in a
range of respiratory diseases, including asthma and
chronic obstructive pulmonary disease (COPD). Studies
from MMP-12 knock-out mice indicate that MMP-12 is a
key mediator in cigarette smoke-induced emphysema
[12].
Human airway smooth muscle cells (ASMC) express
MMP-1, -2, -3, -9 and -14 [13-16]. The induction of MMP-
12 by ASMC is however unknown. Considering the poten-
tial of ASMC to produce a host of soluble inflammatory
mediators in response to inflammatory stimulation and
their involvement in airway remodeling, we investigated
the possibility that ASMC produce MMP-12. Since inflam-
matory cytokines have been shown to stimulate or inhibit
MMP-12 induction in macrophages [17,18] and chondro-
cytes [19]), we examined the possible effects of the
inflammatory cytokines, including interleukin (IL)-1β,
tumour necrosis factor (TNF)-α and transforming growth
factor (TGF)-β1, on MMP-12 induction of ASMC. Further-
more, we investigated the intracellular mechanisms of
MMP-12 induction in ASMC, particularly the role of
mitogen-activated protein kinases (MAPK), such as extra-
cellular signal-regulated kinase (ERK) and c-Jun N-termi-
nal kinase (JNK), and phosphatidylinositol 3-kinase (PI3-
K) pathways.
Methods
Materials
All recombinant human cytokines were purchased from
R&D Systems (Abingdon, UK). PD98059, SB203580,
Wortmannin and LY294002 were obtained from Calbio-
chem (Nottingham, UK). SP600125 was a kind gift from
Celgene (San Diego, CA). Primers for MMP-12 and
GAPDH were purchased from Sigma Genosys (Pampis-
ford, UK). Internal control 18S rRNA primers were pro-
vided by Applied Biosystems (Forster City, CA). Rabbit
anti-human MMP-12 antibodies (AB19053 and
AB19051) were obtained from Chemicon (Hampshire,
UK). Precast gels and buffers for Western blot and zymog-
raphy were purchased from Invitrogen (Paisley, UK).
Nuclear extract kit and TransAM AP-1 family kit were from
Active Motif (Rixensart, Belgium). RNase-free slides, rea-
gents and other materials for Laser capture microdissec-
tion (LCM) were purchased from Arcturus (Hertfordshire,
UK). Dexamethasone and all other tissue culture reagents
were obtained from Sigma (Dorset, UK).
Human airway biopsies were obtained from normal vol-
unteers (n = 4) and patients using the well-established
procedures of fiberoptic bronchoscopy, and protocols
that have been approved by the local Ethics Committee.
The patients included three with moderate asthma, three
with COPD and five with persistent 'idiopathic cough'. All
subjects gave informed consent.
Cell culture and treatment
Primary ASMC were isolated from fresh lobar or main
bronchi, obtained from lung resection donors, by treat-
ment with collagenase and cultured in DMEM supple-
mented with 10% FCS as described previously [20]. ASMC
characteristics were identified by light microscopy with
typical 'hill and valley' appearance and by positive immu-
nostaining of smooth muscle (SM) α-actin, SM myosin
heavy chain, calponin and SM-22. The cells were main-
tained in T175 culture flasks at 37°C in a humidified
atmosphere of 5% CO2. For these experiments, ASMC
were studied from passages 3–6.
Cells were trypsinized and subcultured in 6-well plates for
total protein and RNA extractions or in T75 flasks for
nuclear protein extraction. After reaching confluence in
10% FCS DMEM, cells were incubated for 2–3 days in
serum-free medium containing 0.5% BSA before treat-
ment. Cells were treated with IL-1β or the appropriate testPage 2 of 11
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BSA. Control cultures were incubated in the medium con-
taining vehicle alone.
Laser capture microdissection
Human airway biopsies were embedded in Optimum
Cutting Temperature (OCT) compound on dry ice and
snap-frozen in liquid nitrogen before storage at -80°C.
Frozen sections were cut at 6 µm thickness and mounted
on LCM slides (Arcturus). The slides were immediately
stored on dry ice and then at -80°C until used. Sections
were fixed in 70% ethanol for 30 seconds, and stained and
dehydrated in a series of graded ethanol followed by
xylene using HistoGene LCM frozen section staining kit
(Arcturus) according to the manufacturer's instruction.
ASMC were captured onto the CapSure HS LCM caps (Arc-
turus) by a Pixcell II Laser Capture Microdissection System
(Arcturus, Mountain View, CA) and total RNA was
extracted by using a PicoPure RNA isolation kit (Arcturus)
according to the manufacturer's instructions.
RT-PCR and real-time PCR
Total RNA was extracted from cultured ASMC by using the
RNeasy Mini Kit (Qiagen, West Sussex, UK) according to
the manufacturer's instructions. An aliquot of 0.5 µg total
RNA was reverse transcribed using random hexamers and
AMV reverse transcriptase (Promega). cDNA generated
from 42 ng of total RNA was amplified by polymerase
chain reaction (PCR) (RoboCycler, Stratagene, USA) or
quantitative real-time PCR (Rotor Gene 3000, Corbett
Research, Australia) using SYBR Green PCR Master Mix
Reagent (Qiagen). The human MMP-12 forward and
reverse primers were 5'-TGCTGATGACATACGTGGCA-3'
and 5'-AGGATTTGGCAAGCGTTGG-3' 19). Each primer
was used at a concentration of 2 µM or 0.5 µM for PCR or
real-time PCR in each reaction. Cycling conditions for
PCR were as follows: 95°C for 30 seconds; 60°C for 30
seconds followed by 72°C for 30 seconds for 30 cycles.
The amplification products were analysed by 3% agarose
gel electrophoresis. Cycling conditions for real-time PCR
were as follows: step 1, 15 min at 95°C; step 2, 20 sec at
94°C; step3, 20 sec at 60°C; step 4, 20 sec at 72°C, with
repeat from step 2 to step 4 for 35 times. Data from the
reaction were collected and analysed by the complemen-
tary computer software (Corbett Research, Australia). Rel-
ative quantitations of gene expression were calculated
using standard curves and normalized to GAPDH in each
sample. For real-time PCR analysis of samples obtained
from LCM, 18S rRNA was used as a housekeeping gene for
internal control, and human lung tissue was used as a pos-
itive control.
Western blotting
Total cell protein was extracted on ice with lysis buffer
(1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1%
SDS in PBS pH 7.4) in the presence of freshly added pro-
tease inhibitors including 1 mM phenylmethylsulphonyl
fluoride (PMSF), 5 µg/ml aprotinin, 1 mM Na3VO4 and 5
µg/ml leupeptin. Protein concentration was determined
using the Bradford method with a Bio-Rad protein assay
reagent. Protein extract (20 µg/lane) was fractionated by
SDS-PAGE on a 10% tris-glycine precast gel and then
transferred to a nitrocellulose membrane (Amersham).
The membrane was incubated overnight at 4°C with an
MMP-12 C-terminus antibody (0.5 µg/ml, AB19053) and
then with an HRP-conjugated secondary antibody raised
against rabbit IgG (1:2000, 1 hour) at room temperature.
Antibody-bound proteins were visualised by ECL. The
membranes were stripped and then reprobed with a
mouse anti-GAPDH monoclonal antibody (1:5000, Bio-
genesis, Poole, UK) to control for protein loading. Rele-
vant band intensities were quantified by scanning
densitometric analysis using software from Ultra-Violet
Products (Cambridge, UK). Densitometric data were nor-
malized for GAPDH values.
To analyse the secretion of MMP-12, conditioned
medium (400 µl) was concentrated to 20 µl by Centricon-
10 miniconcentrator (Amicon, Bedford, MA) and frac-
tionated by the 10% precast gel. Western blot analysis was
performed as described above. Relevant band intensities
were quantified by scanning densitometric analysis and
normalised against the cell number (see below).
Zymography
Conditioned media were harvested from ASMC cultures
after treatments and the cell number in each well was
detected by crystal violet assay [21]. MMP-12 activity was
determined by gelatin zymography [22] according to the
manufacturer's instructions (Invitrogen). Conditioned
medium (20 µl) was fractionated by SDS-PAGE on a 10%
precast zymography gel. To renature separated protein,
gels were incubated 2 × 15 min with Renaturing Buffer
(2.5% Triton-X 100; Invitrogen) by shaking, and then
incubated with Developing Buffer (0.2% Brij; Invitrogen)
for 30 min, followed by 18 hours incubation with Devel-
oping Buffer at room temperature by gentle shaking. Gels
were stained in 0.1% Coomassie Brilliant Blue R-250 for
approximately 1 hour and destained until the gelatino-
lytic bands were clearly seen. Gelatinolytic bands at
45kDa represent the active form of MMP-12. Relevant
band intensities were quantified by scanning densitomet-
ric analysis and normalised to cell number.
Immunohistochemistry and immunocytochemistry
Immunostaining was performed to detect the protein
expression of MMP-12 in ASMC from human bronchial
tissue sections or cell cultures on chamber slides. For
Immunohistochemistry, bronchial samples were fixed in
4% formaldehyde and embedded in paraffin wax. 4 µmPage 3 of 11
(page number not for citation purposes)
Respiratory Research 2005, 6:148 http://respiratory-research.com/content/6/1/148sections were cut before deparaffinization and rehydra-
tion. For immunocytochemistry, ASMC on chamber
slides were fixed in 4% paraformaldehyde in PBS for 10
min followed by ice-cold acetone-methanol (50:50) for
10 min. Slides with both bronchial tissue section and
ASMC layer were incubated in 3% hydrogen peroxide to
block endogenous peroxidase activity, followed by 5%
normal goat serum to block non-specific binding. Sec-
tions were incubated for 1 hour at room temperature with
a rabbit anti-human MMP-12 hinge-region antibody (3.3
µg/ml, AB19051). Control slides were performed with
normal rabbit immunoglobulin. Anti-rabbit biotinylated
secondary antibody (Vector ABC Kit, Vector Laboratories)
was applied to the sections for 30 min at room tempera-
ture, followed by the avidin/biotinylated peroxidase com-
plex for another 30 min at room temperature. Sections
were incubated with chromogenic substrate diaminoben-
zidine (DAB) for 5 min, and then counterstained in hae-
matoxylin and mounted on aqueous mounting medium.
c-Jun activation assay
Nuclear protein extracts were obtained from ASMC cul-
tures by using the Nuclear Extract Kit (Active Motif)
according to the manufacturer's instruction. Aliquots of
nuclear protein were stored at -80°C. The activation of c-
Jun was measured using the TransAM™ AP-1 family kit
(Active Motif) according to the manufacturer's instruc-
tion. This method measures the DNA-binding activity of
activator protein (AP)-1 by ELISA. Briefly, 5 µg of nuclear
protein samples were incubated for 1 hour in a 96-well
plate coated with an oligonucleotide that contains a TRE
(5'-TGAGTCA-3'), to which phosphorylated c-Jun (p-c-
Jun) contained in nuclear extracts specifically binds. After
washing, p-c-Jun antibody (1:500 dilutions) was added to
these wells and incubated for 1 hour. Following incuba-
tion for 1 hour with a secondary HRP-conjugated anti-
body (1:1000 dilution), specific binding was detected by
colorimetric estimation at 450 nm with a reference wave-
length of 655 nm.
Data analysis
Data were analysed by analysis of variance (ANOVA)
using the software program, Statview (Abacus Concept,
Inc., Berkeley, CA, USA). Results are expressed as mean ±
SEM and are representative of at least three separate exper-
iments. P < 0.05 was used to determine the statistical sig-
nificance.
Results
Expression of MMP-12 mRNA and protein by in-situ 
ASMC
To determine whether human airway smooth muscle cells
express MMP-12 mRNA in-situ, LCM was performed on
Expression of MMP-12 mRNA by in-situ ASMCFigure 1
Expression of MMP-12 mRNA by in-situ ASMC. Laser capture 
microdissection was performed to collect ASMC from bron-
chial biopsy sections (A). MMP-12 mRNA expression was 
analysed by real-time RT-PCR (B). The data, obtained from 4 
normal volunteers, 3 asthma, 3 COPD and 5 chronic cough 
patients, were normalized to the housekeeping gene 18S 
rRNA representative of relative MMP-12 mRNA expression 
(C). Lung tissue was used as a positive control. Expression of MMP-12 protein in bronchial smooth muscle tissu  and cell cultures by immu ostainingFig re 2
Expression of MMP-12 protein in bronchial smooth muscle 
tissue and cell cultures by immunostaining. Sections from 
human bronchial samples were prepared (A). Cell cultures 
were incubated on 8-well chamber slides for 72 hours in the 
absence (B) or presence (C) of 10 ng/ml IL-1β. Immunostain-
ing was performed to detect MMP-12 expression using a rab-
bit anti-MMP-12 antibody. The primary antibody was 
replaced by a normal rabbit immunoglobulin as a negative 
control (D). Bar = 50 mm. Results are representative from 
three donors.Page 4 of 11
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smooth muscle cell populations (Figure 1A). Quantitative
real-time RT-PCR analysis revealed that these in-situ ASMC
expressed MMP-12 mRNA (Figure 1B,C). The smooth
muscle cells obtained from normal volunteers showed
some expression of MMP-12, but there was elevated
expression in the cells obtained from patients with
asthma, COPD and chronic cough, however statistical sig-
nificance was not achieved.
Immunohistochemistry of human bronchial samples
showed positive immunostaining for MMP-12 in smooth
muscle cells (Figure 2A), with no staining in the negative
control section in which the rabbit anti-MMP-12 antibody
was replaced by a normal rabbit immunoglobulin (data
not shown).
Stimulation of MMP-12 gene and protein expression by IL-
1β in primary ASMC cultures
IL-1β (10 ng/ml) induced a time-dependent increase in
MMP-12 mRNA expression analysed either by RT-PCR
(Figure 3A) or quantitative real-time RT-PCR (Figure 3B).
The increase was observed as early as 1 hour following
treatment, with a maximal increase after 24 hours (Figure
3B). The effect of IL-1β was also concentration-dependent
over the range of 0.01 to 10 ng/ml (Figure 3C). A 30-fold
enhancement was observed at 0.01 ng/ml with a maximal
effect of 130-fold at 10 ng/ml compared to unstimulated
controls.
Stimulation of MMP-12 mRNA expression by IL-1β in ASMCFigure 3
Stimulation of MMP-12 mRNA expression by IL-1β in ASMC. 
Cells were incubated in the absence or presence of IL-1β at 
10 ng/ml for 1–24 hours (A, B), or for 24 hours over 0.01 to 
10 ng/ml (C). MMP-12 and GAPDH mRNA expression was 
analysed by RT-PCR (A) or real-time RT-PCR (B,C). Results 
(B,C) were expressed as a ratio of target gene to GAPDH 
mRNA control and are the mean ± SEM from three ASMC 
donors. **P < 0.01 compared with control.
Western blot analysis of MMP-12 protein expression in ASMC and the effect of IL-1βFigure 4
Western blot analysis of MMP-12 protein expression in 
ASMC and the effect of IL-1β. Cells were incubated in 6-well 
plates in the absence or presence of 10 ng/ml IL-1β for 24–72 
hours. MMP-12 protein expression was analysed by Western 
blot (A) and shown as a ratio of GAPDH obtained by densit-
ometric analysis (B). Results are mean ± SEM from three 
ASMC donors.Page 5 of 11
(page number not for citation purposes)
Respiratory Research 2005, 6:148 http://respiratory-research.com/content/6/1/148To determine whether IL-1β regulates MMP-12 protein
production, ASMC cultured on chamber slides were
treated with IL-1β (10 ng/ml) for 72 hours and MMP-12
expression in these cells was detected by immunocyto-
chemistry. Cultured ASMC expressed MMP-12 protein in
the absence (Figure. 2B) and presence (Figure. 2C) of IL-
1β.
Western blot analysis using an anti-human MMP-12 anti-
body, that specifically recognises both the 54 kDa latent
form and the 45 kDa active form of MMP-12, showed that
unstimulated ASMC expressed both latent and active
forms of MMP-12 (Figure 4). IL-1β caused a 2-fold
increase in the expression of the active form after 24
hours, and this was sustained for up to 72 hours. There
was no significant effect of IL-1β on the expression of the
latent form of MMP-12.
Secretion of MMP-12 protein by ASMC and enhancement 
by IL-1β
To assess MMP-12 secretion and activity of ASMC, we per-
formed gelatin zymography on conditioned media. As
shown in Figure 5A, ASMC secreted several MMPs. In
accordance with their molecular weights and with previ-
ous studies, these MMPs included 62 kDa MMP-2, 72 kDa
pro-MMP-2, 88 kDa MMP-9 and 92 kDa pro-MMP-9, in
descending order of magnitude of activity observed. In
addition, a 45 kDa MMP-12 active form was observed; the
molecular weight was confirmed by running an MMP-12
Activity of MMP-12 secreted by ASMC and stimulation by IL-1βFigure 5
Activity of MMP-12 secreted by ASMC and stimulation by IL-
1β. (A) Gelatin zymography detection of activity of MMPs 
released into the conditioned media by ASMC treated for 48 
hours (lane 1, protein markers; lane 2, control; lane 3, 10 ng/
ml IL-1β; lane 4, 10 ng/ml TGF-β; lane 5, TGF-β plus IL-1β; 
lane 6, 10 ng/ml TNF-α; lane 7, TNF-α plus IL-1β; lane 8, 10 
ng/ml IL-13). (B) Time-dependent stimulation of MMP-12 
activity by 10 ng/ml IL-1β. Lane s, human MMP-12 standard 
protein used as a positive control. Lane n, negative control. 
(C) Concentration-dependent stimulation of MMP-12 activity 
by IL-1β for 48 hours. Relevant band intensities were quanti-
fied by scanning densitometric analysis and normalized to 5 × 
105 cells. Results are the mean ± SEM from three ASMC 
donors. *P < 0.05, **P < 0.01 compared with control.
Inhibition of IL-1β-stimulated MMP-12 activity and mRNA expression by PD98059 nd SP600125Figure 6
Inhibition of IL-1β-stimulated MMP-12 activity and mRNA 
expression by PD98059 and SP600125. ASMC were pre-
treated for 1 hour with a specific inhibitor for ERK, PD98059 
(1 or 10 µM) or for JNK, SP600125 (10 µM), and then were 
co-treated with 10 ng/ml IL-1β. (A) MMP-12 activity in condi-
tioned media was detected after 48 hours by zymography. 
The relevant band intensities were quantified by scanning 
densitometric analysis. (B) MMP-12 mRNA was analysed 
after 24 hours by real-time RT-PCR. The data are expressed 
as the percentage of IL-1β alone and are the mean ± SEM 
from three ASMC donors. *P < 0.05, **P < 0.01 compared 
with IL-1β alone.Page 6 of 11
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ASMC secreted a detectable active form of MMP-12, with
a time-dependent enhancement of the secretion after
exposing cells with 10 ng/ml IL-1β (Figure 5B). A signifi-
cant increase in MMP-12 activity was seen following 24
hour treatment, reaching a maximal ten-fold increase after
72 hours. Similar to the effects on MMP-12 mRNA, IL-1β
also caused a concentration-dependent increase in the
enzyme release from ASMC after 48 hours (Figure 5C): at
0.01 ng/ml, the activity increased by 2.5-fold, with a max-
imal effect at 10 ng/ml of an 8.5-fold increase. We also
used casein zymography to detect MMP-12 activity and
similar results were obtained albeit at a lower sensitivity
compared to gelatin zymography (data not shown).
Inhibition of IL-1β-stimulated MMP-12 activity and mRNA expression by wortmannin, LY29400 nd dex methasoneFigure 7
Inhibition of IL-1β-stimulated MMP-12 activity and mRNA 
expression by wortmannin, LY294002 and dexamethasone. 
ASMC were pre-treated for 1 hour with PI3-K inhibitors, 
wortmannin or LY294002, or dexamethasone at the indi-
cated concentrations, and then were co-treated with 10 ng/
ml IL-1β. (A) MMP-12 activity in conditioned media was 
detected after 48 hours by zymography. The relevant band 
intensities were quantified by scanning densitometric analysis. 
(B) MMP-12 mRNA was analysed after 24 hours by real-time 
RT-PCR. The data are expressed as the percentage of IL-1β 
alone and are the mean ± SEM from three ASMC donors. *P 
< 0.05, **P < 0.01 compared with IL-1β alone.
Effects of TNF-α and TGF-β1 on IL-1β-stimulated MMP-12 activity, mR A expression and c-Jun activationFigure 8
Effects of TNF-α and TGF-β1 on IL-1β-stimulated MMP-12 
activity, mRNA expression and c-Jun activation. ASMC were 
treated with 10 ng/ml of TNF-α or TGF-β1 alone, or in com-
bination with 10 ng/ml IL-1β. (A) MMP-12 activity in condi-
tion media was detected by zymography after 48 hours, and 
the relevant band intensities were quantified by densitomet-
ric analysis and normalized to 5 × 105 cells. (B) MMP-12 
mRNA expression was determined by real-time RT-PCR 
after 24 hours and expressed as a ratio to GAPDH mRNA. 
(C) c-Jun activation and DNA-binding analysed by the 
TransAM AP-1 family kit. Data are the mean ± SEM from 
three ASMC donors. *P < 0.05, **P < 0.01 compared with 
control; +P < 0.05, ++P < 0.01, compared with IL-1β alone.Page 7 of 11
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MAPKs, PI3-K and corticosteroid
ASMC were pre-incubated for 1 hour with specific inhibi-
tors for ERK (PD98059), JNK (SP600125), p38 MAPK
(SB203580) or for PI3-K (wortmannin and LY294002), or
with the corticosteroid, dexamethasone, and then co-
treated with IL-1β(10 ng/ml) for 24 hours for analysis of
mRNA expression or for 48 hours for protein activity.
Treatment of ASMC with PD98059 (1–10 µM) or
SP600125 (10 µM) inhibited IL-1β-induced MMP-12
activity (Figure 6A) and mRNA expression (Figure 6B). A
significant inhibition in activity was seen with 1 µM
PD98059 and 10 µM SP600125, with a >75% inhibition
with 10 µM PD98059. SB203580 had no significant effect
up to 1 µM (data not shown). Wortmannin (100–500
nM) and LY294002 (5–20 µM) induced a concentration-
dependent inhibition of IL-1β-stimulated MMP-12 activ-
ity (Figure 7A). Dexamethasone (10-6 M) also significantly
blocked IL-1β-stimulated MMP-12 activity (Figure 7A). A
similar suppression in IL-1β-induced MMP-12 mRNA
expression was observed with wortmannin (250 nM),
LY294002 (10 µM) and dexamethasone (10-6 M) (Figure
7B).
Effects of TNF-α, TGF-β1, IL-4 and IL-13 on IL-1β-induced 
MMP-12 release, gene expression and c-Jun activation
ASMC were incubated with 10 ng/ml of TNF-α, TGF-β1,
IL-4 or IL-13 alone, or in combination with IL-1β (10 ng/
ml) for 48 hours. TNF-α stimulated MMP-12 release by 4-
fold in comparison with control levels, and also enhanced
IL-1β-induced MMP-12 release. In contrast, TGF-β1 had
no significant effect on basal or IL-1β-stimulated MMP-12
activity (Figure 8A). Similar results were observed for
MMP-12 gene expression of ASMC after 24 hour treat-
ment (Figure 8B). IL-1β-stimulated c-Jun activation and
DNA binding was enhanced 85% by TNF-α (Figure 8C).
TNF-α alone also had a significant effect on c-Jun activa-
tion and DNA binding. TGF-β1 had no significant effect
on basal or IL-1β-induced c-Jun activation (Figure 8C).
The T helper lymphocyte 2-derived (Th2) cytokines, IL-4
and IL-13, also had no effect on MMP-12 activity, gene
expression or c-Jun activation either in the presence or
absence of IL-1β (data not shown).
Western blot analysis of MMP-12 secretion by airway 
smooth muscle cells
We also performed Western blot analysis to determine
MMP-12 secretion by using a specific MMP-12 antibody
(Figure 9). Conditioned media were collected from 6-well
plates after ASMC were treated for 48 hours with IL-1β
and/or TNF-α in the absence or presence of the specific
inhibitors. The results of MMP-12 secretion analysed by
Western blot was consistent with the data obtained by gel-
atin zymography and confirmed that ASMC secreted the
45 kDa active form of MMP-12 which was up-regulated by
inflammatory cytokines, IL-1β and TNF-α. The specific
inhibitors for ERK, JNK and PI3-K also down-regulated
MMP-12 secretion by IL-1β.
Discussion
We performed laser capture microdissection to collect
smooth muscle cells from bronchial biopsy sections and
found that in-situ ASMC expressed both MMP-12 mRNA
and protein. MMP-12 mRNA expression was found in
ASMC obtained from normal subjects, and was somewhat
higher in patients with asthma, COPD and chronic idio-
pathic cough. More patients are likely to be needed to
demonstrate statistical significance. In cultured primary
ASMC, we have also shown that MMP-12 mRNA and pro-
tein expression and secretion were regulated by the
inflammatory cytokine, IL-1β. IL-1β induced a >100-fold
increase in the mRNA levels and a >10-fold enhancement
in the enzyme release and activation from ASMC cultures,
that was mediated by mechanisms involving ERK, JNK,
PI3-K and AP-1 pathways. Therefore, airway smooth mus-
cle cells, similar to vascular smooth muscle cells, are an
important source of MMP-12 [23].
Western blot analysis of MMP-12 secretion by ASMCFigure 9
Western blot analysis of MMP-12 secretion by ASMC. Cells 
were incubated for 48 hours with 10 ng/ml IL-1β or TNF-α 
alone, or IL-1β combination with TNF-α, PD98059 (1 µM), 
SP600125 (10 µM) or wortmannin (250 nM) for 48 hours. 
MMP-12 protein released into conditioned media was deter-
mined by Western blot using 20 µl of 40-fold concentrated 
samples. Relevant band intensities were quantified by scan-
ning densitometric analysis and normalized to 5 × 105 cells. 
Results are the mean ± SEM from three ASMC donors. **P < 
0.01 compared with control; +P < 0.05, +P < 0.01 compared 
with IL-1β alone.Page 8 of 11
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milieu of the airways include inflammatory cytokines and
growth factors. The inflammatory cytokines, IL-1β and
TNF-α, and the growth factor, TGF-β1, are thought to play
active roles in asthma and emphysema/COPD [24-26],
and induce the induction of a number of inflammatory
mediators by ASMC [27,28]. Increased expression of IL-1β
has been detected in airway epithelial cells and alveolar
macrophages of patients with asthma [29,30]. The expres-
sion of TNF-α and TGF-β1 are elevated in lung and bron-
choalveolar lavage fluid in asthma [31,32]. We found that
IL-1β induced a time- and concentration-dependent
increase in MMP-12 mRNA expression. Although the
maximal stimulation of MMP-12 mRNA expression by IL-
1β reached 130-fold of control levels, the protein expres-
sion of the 45 kDa active form was only increased by 2-
fold, with a slightly increase in the 54 kDa latent form,
likely to be due to its conversion to the 45 kDa active
form. Since the pathological significance of MMP expres-
sion depends on its secretion and activity and since most
cells synthesize and immediately secrete MMPs into the
extracellular environment [33], we next examined
whether IL-1β enhanced MMP-12 release from ASMC.
Indeed, IL-1β enhanced MMP-12 secretion and activity of
ASMC in a time- and concentration-dependent manner,
with an up to 10-fold increase to control levels, as deter-
mined by gelatin zymography. Our data are similar to pre-
vious studies on MMP-12 release by macrophages [17,18].
The difference in levels of mRNA and protein suggest a
complex regulation of MMP-12 translation and secretion.
This allows control to be exerted at distinct levels prevent-
ing excessive release of MMP-12 unless further stimula-
tory signals are received.
We also found that TNF-α stimulated MMP-12 gene
expression and activity of ASMC although to lesser extent
than IL-1β, as has been described in chondrocytes [19].
TNF-α also had an additive effect with IL-1β in MMP-12
activity, although in terms of MMP-12 mRNA expression,
this was synergistic. TGF-β1 had no significant effect on
MMP-12 activity and gene expression, which is in contrast
to the report of TGF-β1 inhibition of IL-1β-mediated
MMP-12 induction in macrophages [18]. This suggests
differential effects of TGF-β1 on MMP-12 regulation in
different cell types. We did not observe regulation of
MMP-12 mRNA levels and enzyme secretion when ASMC
were exposed to the Th2 cytokines IL-4 or IL-13, either
alone or in combination with IL-1β, although these
cytokines can induce MMPs in mouse lung tissue [34].
MMP-12 induction in human bronchial epithelial cells by
TNF-α, epidermal growth factor and interferon-γ but not
by IL-4 or IL-13 has recently been reported [35]. Overall,
these data imply that MMP-12 release from ASMC is
under the control of select pro-inflammatory stimuli and
is regulated differently between human and murine cells.
AP-1 is a dimeric complex composed of Jun (c-Jun, JunB
or JunD) and Fos (FosB, c-Fos, Fra-1 or Fra-2) proteins,
which may be involved in the modulation of MMP-12 as
has been shown in macrophages [18] and vascular
smooth muscle cells [23]. Removal of the AP-1 binding
site from the MMP-12 promoter abolished the basal and
inducible expression of MMP-12 [23]. c-Jun, which is a
predominant component of the AP-1 binding complex
binding to the MMP-12 promoter [23], can potentially
transactivate the MMP-12 promoter up to 20-fold in mac-
rophages [18]. Therefore, we examined whether these
cytokines affected MMP-12 secretion mediated through
regulation of c-Jun activity in ASMC. We found that IL-1β
and TNF-α enhanced c-Jun activation and nuclear bind-
ing, and when combined together, they had an additive
effect. TGF-β1 alone had no effect, and barely augmented
IL-1β-induced c-Jun activation. The effects of these
cytokines on c-Jun activation were directly correlated with
their activities on MMP-12 release. This combination with
the effect of JNK inhibitor implies a role for c-Jun in medi-
ating cytokine-stimulated MMP-12 induction in ASMC.
The intracellular mechanisms and signaling pathways that
mediate IL-1β-induced MMP-12 in ASMC are unknown.
IL-1β stimulates the induction of MMP-1 in human gingi-
val fibroblasts by activation of MAPKs [36]. MAPKs are a
family of serine/threonine kinases, and at least three sub-
families that differ in their substrate specificity have been
characterized: ERK, JNK and P38 MAPK. Here, we show
that ERK and JNK, but not p38 MAPK, pathways are
involved in IL-1β-induced MMP-12 secretion and gene
expression. IL-1β-induced MMP-3 and -13 gene and pro-
tein expression in articular chondrocytes and MMP-9
expression in rat brain astrocytes have also been reported
to be regulated by ERK and JNK pathways [37,38]. We
have previously shown that at a concentration of 10 µM,
SP600125 induces specific inhibition of IL-1β-induced
JNK activation in ASMC, having no effect on p38 MAPK
and ERK activation [39]. We did not use concentrations of
SB20358 higher than that of 1 µM, since above this con-
centration this compound inhibits the JNK pathway [40].
Therefore, our data indicate that the induction of MMP-12
by IL-1β in ASMC may not involve the participation of the
p38 MAPK pathway, which is contrary to the regulation of
MMP-3, -9 and -13 in articular chondrocytes and rat brain
astrocytes [37,38]. These differences may reflect different
cell types and MMPs studied.
PI3-kinase is involved in the regulation of a number of
cellular responses, including MMP-12 induction in
human vascular smooth muscle cells [23]. We used two
structurally different inhibitors of PI3-K: wortmannin, a
non-reversible inhibitor which covalently binds to the cat-
alytic subunit of PI3-K [41], and LY294002, a reversible
inhibitor that competes with ATP for the PI3-K substrate-Page 9 of 11
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required for IL-1β-stimulated MMP-12 mRNA expression
and secretion in ASMC. In vascular smooth muscle cells,
PI3-kinase activation appears to be required for MMP-12
transcriptional activity through AP-1 binding to the gene
promoter [23].
Corticosteroids are anti-inflammatory drugs used for the
treatment of asthma and COPD, and previous studies
have shown their inhibitory effects on MMP-12 induction
by lipopolysaccharide in human alveolar macrophages
[7]. We observed marked down-regulation of IL-1β-stim-
ulated MMP-12 mRNA expression and enzyme activity by
dexamethasone. This indicates that corticosteroid treat-
ment may lead to prevention of airway wall remodelling
and the development of MMP-12-dependent emphysema
in COPD although evidence for this in the airways of asth-
matic and COPD patients is limited. It is not known,
whether MMP-12 release from airway smooth muscle
cells in COPD may be similarly inhibited by corticoster-
oids, since there is relative corticosteroid resistance in
COPD.
Conclusion
We have provided evidence that in vivo ASMC express
MMP-12 mRNA and protein. The pro-inflammatory
cytokine IL-1β stimulates a significant enhancement in
MMP-12 gene expression, protein production and
enzyme secretion, which is mediated by mechanisms
involving ERK, JNK, PI3-K and AP-1 signaling pathways.
Induction of MMP-12 by IL-1β is up-regulated by the
inflammatory cytokine TNF-α and down-regulated by the
corticosteroid dexamethasone. Exposure to the inflamma-
tory cytokines, IL-1β and TNF-α, stimulates the release of
MMP-12 which in turn activates other MMPs [10] to
breakdown extracellular matrix proteins and promote
inflammatory cells migration, and induces enhanced elas-
tolytic activity and excessive airway remodeling. Thus,
MMP-12 induction by inflammatory cytokines may be a
potential pathophysiological mechanism by which ASMC
mediate and facilitate inflammatory respiratory disorders
such as asthma and COPD.
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